Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

INIS

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science